BeyondSpring Files 2023 Annual Report on Form 20-F
29 Abril 2024 - 6:30PM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”
or the “Company”), a clinical-stage global biopharmaceutical
company focused on developing innovative cancer therapies, today
announced that it has filed its annual report on Form 20-F for the
fiscal year ended December 31, 2023 with the U.S. Securities and
Exchange Commission (“SEC”) on April 29, 2024. The annual report on
Form 20-F, which contains the Company’s audited consolidated
financial statements, can be accessed on the SEC’s website at
www.sec.gov and on the Company’s website at
www.beyondspringpharma.com under “Financials & Filings” in the
Investors section.
The Company will provide a hard copy of its annual
report containing its audited consolidated financial statements,
free of charge, to its shareholders upon request. Requests should
be directed to Investor Relations, BeyondSpring Inc., 100 Campus
Drive, Suite 410, Florham Park, NJ 07932 USA.
About BeyondSpringBeyondSpring
is a global clinical-stage biopharmaceutical company focused on
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs. The Company is advancing
its first-in-class lead asset, Plinabulin, as a direct anti-cancer
agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. BeyondSpring’s pipeline also
includes three preclinical immuno-oncology assets. Additionally,
BeyondSpring’s subsidiary, SEED Therapeutics, leverages a
proprietary targeted protein degradation (TPD) drug discovery
platform and has an initial R&D collaboration with Eli Lilly.
Learn more by visiting https://beyondspringpharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes forward-looking
statements that are not historical facts. Words such as “will,”
“expect,” “anticipate,” “plan,” “believe,” “design,” “may,”
“future,” “estimate,” “predict,” “objective,” “goal,” or variations
thereof and variations of such words and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are based on BeyondSpring’s current
knowledge and its present beliefs and expectations regarding
possible future events and are subject to risks, uncertainties and
assumptions. Actual results and the timing of events could differ
materially from those anticipated in these forward-looking
statements as a result of several factors including, but not
limited to, our ability to continue as a going concern,
difficulties raising the anticipated amount needed to finance the
Company’s future operations on terms acceptable to the Company, if
at all, unexpected results of clinical trials, delays or denial in
regulatory approval process, results that do not meet the Company’s
expectations regarding the potential safety, the ultimate efficacy
or clinical utility of the Company’s product candidates, increased
competition in the market, the Company’s ability to meet Nasdaq's
continued listing requirements, and other risks described in
BeyondSpring’s most recent Form 20-F on file with the U.S.
Securities and Exchange Commission. All forward-looking statements
made herein speak only as of the date of this release and
BeyondSpring undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or
circumstances, except as otherwise required by law.
Investor
Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024